Look back at pharma news to Nov 24

Last week’s major news included the long-awaited decision on the new location for the European Medicines Agency, and more lay-offs at Israeli generics giant Teva Pharmaceutical Industries. On the research front, Roche hit the headlines with important new data on its cancer drug Tecentriq and hemophilia treatment Hemlibra, and the failure of Cytokinetics’ ALS drug candidate tirasemtiv. There was also positive regulatory news for Janssen, with the company gaining European approval for its prostate cancer drug Zytiga as a first-line therapy, and GlaxoSmithKline being granted Food and Drug Administration clearance for Juluca, the fist single-pill doublet to treat HIV.

Who could lose as European drug regulation moves to Amsterdam

In a process arguably crueller than a football penalty shootout, one hand in a goldfish bowl decided that Amsterdam, rather than Milan, would claim the honor of being the new home for the European Medicines Agency, commented EP Vantage, the editorial arm of the Evaluate group.